The Potential of Siraitia grosvenorii to Promote Bone Regeneration via Modulating Macrophage Polarization: A Network Pharmacology and Experimental Study
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26083609 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yuying Mai und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Stomatology, Guangxi Medical University, Shuangyong Road 22, Nanning 530021, China. Hauptthemen laut MEDLINE: Macrophages, Bone Regeneration, Drugs, Chinese Herbal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation, Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction Research Open Project.
Abstract (Originalsprache)
Siraitia grosvenorii (SG), a traditional Chinese medicinal herb, possesses immunomodulatory and osteoinductive properties, yet its pharmacological mechanisms in bone defect repair remain largely unexplored. This study investigates the therapeutic potential of SG through a combination of network pharmacology and experimental approaches. Active compounds were identified using the Traditional Chinese Medicine Systems Pharmacology (TCMSP) Platform, and protein interaction targets were predicted. Molecular docking and dynamics simulations assessed interactions between SG compounds and critical targets. In vitro, RAW 264.7 macrophages treated with SG-conditioned medium exhibited enhanced M2 polarization and reduced inflammation, promoting osteogenic differentiation of co-cultured MC3T3-E1 cells as evidenced by increased alkaline phosphatase activity. In vivo, scaffolds loaded with low-dose or high-dose SG (LSG/HSG) significantly improved bone regeneration in rat calvarial defects, with HSG achieving near-complete repair and mature trabeculae at 8 weeks, alongside decreased CD86 and TNF-α levels and increased IL-10 expression. Network pharmacology identified 33 shared targets related to bone regeneration and macrophage polarization, with kaempferol and beta-sitosterol demonstrating strong binding affinities to targets such as TNF, PTGS2, and CASP3. These findings highlight the potential of SG in enhancing bone defect repair and its implications for regenerative medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Stomatology, Guangxi Medical University, Shuangyong Road 22, Nanning 530021, China.
- Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction, Nanning 530021, China.
ORCID-Profile: Yuying Mai, Lufei Wang
Förderung
- National Natural Science Foundation of China
- Joint Project on Regional High-Incidence Diseases Research of Guangxi Natural Science Foundation
- Guangxi Key Laboratory of Oral and Maxillofacial Rehabilitation and Reconstruction Research Open Project
Zitieren
APA
Mai, Y., Huang, L., Qiao, Y., Qin, Y., Wang, L., & Liao, H. (2025). The Potential of Siraitia grosvenorii to Promote Bone Regeneration via Modulating Macrophage Polarization: A Network Pharmacology and Experimental Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083609
Vancouver
Mai Y, Huang L, Qiao Y, Qin Y, Wang L, Liao H. The Potential of Siraitia grosvenorii to Promote Bone Regeneration via Modulating Macrophage Polarization: A Network Pharmacology and Experimental Study. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083609
BibTeX
@article{Mai2025,
author = {Mai, Yuying and Huang, Linhui and Qiao, Yang and Qin, Yuan and Wang, Lufei and Liao, Hongbing},
title = {The Potential of Siraitia grosvenorii to Promote Bone Regeneration via Modulating Macrophage Polarization: A Network Pharmacology and Experimental Study},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26083609}
}
EUVIMED